Eitetsu Koh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eitetsu Koh has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Yuji Maeda
Departments of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa Ishikawa Japan
13 shared publications- Mikio Namiki
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
12 shared publications Mikio Namiki
Departments of Integrative Cancer Therapy and Urology Kanazawa University Graduate School of Medical Science Kanazawa Ishikawa Japan
10 shared publicationsKazuhiro Sugimoto
C Department of Urology , Itaya Clinic , Kaga , Japan
8 shared publicationsAtsumi Yoshida
Reproduction Center Kiba Park Clinic Tokyo Japan
7 shared publications- Atsushi Mizokami
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
6 shared publications
Latest Publications
- 28 March 2017
- Published by Taylor & Francis in The Aging Male
- Vol. 5, 1-7
Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study)
We investigated the effects of testosterone replacement therapy (TRT) on bone mineral density (BMD) among hypogonadal men with osteopenia/osteoporosis.
- 28 March 2017
- Published by Taylor & Francis in The Aging Male
- Vol. 5, 1-7
Effects of testosterone replacement therapy on hypogonadal men with osteopenia or osteoporosis: a subanalysis of a prospective randomized controlled study in Japan (EARTH study)
We investigated the effects of testosterone replacement therapy (TRT) on bone mineral density (BMD) among hypogonadal men with osteopenia/osteoporosis.
- 18 February 2016
- Published by Taylor & Francis in The Aging Male
- Vol. 19 (2) , 128-133
Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction
This study analyzed the effects of dutasteride on lower urinary tract symptoms based on the association between changes in the total testosterone (TT)/dihydrotestosterone (DHT) levels and total prostate volume (TPV) reduction. Sixty participants diagnosed with benign prostatic hyperplasia were given 0.5 mg of dutasteride daily for 52 weeks. Measures of TT and DHT levels, TPV and uroflowmetry were obtained before and after dutasteride treatment. Forty-three patients demonstrated a TPV reduction of ≥5% (Group 1), whereas the remaining 17 patients demonstrated a TPV reduction of <5% (Group 2). DHT suppression and DHT/TT ratio at baseline were significantly higher in Group 1 than Group 2. International Prostate Symptom Scores (IPSS) and uroflowmetry were significantly improved in both groups. In Group 2, nine patients demonstrated some improvement in IPSS (Group 2A), whereas eight did not (Group 2B). The rate of TT increase and improvement in voiding symptoms were significantly higher in Group 2A than Group 2B. Dutasteride-induced TPV reduction is dependent on individual 5-α reductase inhibitor activity. Some patients demonstrating smaller dutasteride-induced TPV reduction may experience an improvement in voiding symptoms owing to an increased level of testosterone.
- 18 February 2016
- Published by Taylor & Francis in The Aging Male
- Vol. 19 (2) , 128-133
Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction
This study analyzed the effects of dutasteride on lower urinary tract symptoms based on the association between changes in the total testosterone (TT)/dihydrotestosterone (DHT) levels and total prostate volume (TPV) reduction. Sixty participants diagnosed with benign prostatic hyperplasia were given 0.5 mg of dutasteride daily for 52 weeks. Measures of TT and DHT levels, TPV and uroflowmetry were obtained before and after dutasteride treatment. Forty-three patients demonstrated a TPV reduction of ≥5% (Group 1), whereas the remaining 17 patients demonstrated a TPV reduction of <5% (Group 2). DHT suppression and DHT/TT ratio at baseline were significantly higher in Group 1 than Group 2. International Prostate Symptom Scores (IPSS) and uroflowmetry were significantly improved in both groups. In Group 2, nine patients demonstrated some improvement in IPSS (Group 2A), whereas eight did not (Group 2B). The rate of TT increase and improvement in voiding symptoms were significantly higher in Group 2A than Group 2B. Dutasteride-induced TPV reduction is dependent on individual 5-α reductase inhibitor activity. Some patients demonstrating smaller dutasteride-induced TPV reduction may experience an improvement in voiding symptoms owing to an increased level of testosterone.
- Open Access
- 29 April 2014
- Published by Wiley in International Journal of Urology
- Vol. 21 (9) , 910-916
New molecular diagnostic kit to assess Y‐chromosome deletions in the Japanese population
博士論文本文 以下に掲載:International Journal of Urology 21(9) pp.910-916 2014.Wiley. 共著者:Masashi Iijima, Eitetsu Koh, Kouji Izumi, Masaki Taya, Yuji Maeda, Kouichi Kyono, Atsumi Yoshida, Mikio Namik
- 29 April 2014
- Published by Wiley in International Journal of Urology
- Vol. 21 (9) , 910-916
Open AccessNew molecular diagnostic kit to assess Y‐chromosome deletions in the Japanese population
博士論文本文 以下に掲載:International Journal of Urology 21(9) pp.910-916 2014.Wiley. 共著者:Masashi Iijima, Eitetsu Koh, Kouji Izumi, Masaki Taya, Yuji Maeda, Kouichi Kyono, Atsumi Yoshida, Mikio Namik
- Open Access
- 9 January 2014
- Published by Wiley in International Journal of Urology
- Vol. 21 (7) , 689-695
Comparison of testosterone fractions between Framingham Heart Study participants and Japanese participants
博士論文本文 以下に掲載:International Journal of Urology 21(7) pp.689-695 2014. Wiley. 共著者:Masaki Taya, Eitetsu Koh, Kouji Izumi, Masashi Iijima, Yuji Maeda, Tomohiko Matsushita, Teruaki Iwamoto, Mikio Namik
- 9 January 2014
- Published by Wiley in International Journal of Urology
- Vol. 21 (7) , 689-695
Open AccessComparison of testosterone fractions between Framingham Heart Study participants and Japanese participants
博士論文本文 以下に掲載:International Journal of Urology 21(7) pp.689-695 2014. Wiley. 共著者:Masaki Taya, Eitetsu Koh, Kouji Izumi, Masashi Iijima, Yuji Maeda, Tomohiko Matsushita, Teruaki Iwamoto, Mikio Namik
- Open Access
- 17 June 2013
- Published by Medknow in Asian Journal of Andrology
- Vol. 15 (5) , 634-639
Aberrant methylation of the TDMR of the GTF2A1L promoter does not affect fertilisation rates via TESE in patients with hypospermatogenesis
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- 17 June 2013
- Published by Medknow in Asian Journal of Andrology
- Vol. 15 (5) , 634-639
Open AccessAberrant methylation of the TDMR of the GTF2A1L promoter does not affect fertilisation rates via TESE in patients with hypospermatogenesis
AJA publishes new findings in basic and clinical (including modern, traditional and epidemiological) research on Andrology.
- Open Access
- 6 May 2012
- Published by Wiley in Journal of Andrology
- Vol. 33 (3) , 483-487
Single‐Nucleotide Polymorphisms in the SEPTIN12 Gene May Be a Genetic Risk Factor for Japanese Patients With Sertoli Cell–Only Syndrome
Genetic mechanisms have been implicated as a cause of some cases of male infertility. Recently, 10 novel genes involved in human spermatogenesis, including human SEPTIN12, were identified by expression microarray analysis of human testicular tissue. Septin12 is a member of the septin family of conserved cytoskeletal GTPases that form heteropolymeric filamentous structures in interphase cells. It is expressed specifically in the testis. Therefore, we hypothesized that mutation or polymorphisms of SEPTIN12 participate in male infertility, especially Sertoli cell–only syndrome (SCOS). To investigate whether SEPTIN12 gene defects are associated with azoospermia caused by SCOS, mutational analysis was performed in 100 Japanese patients by direct sequencing of coding regions. Statistical analysis was performed in patients with SCOS and in 140 healthy control men. No mutations were found in SEPTIN12; however, 8 coding single‐nucleotide polymorphisms (SNP1–SNP8) could be detected in the patients with SCOS. The genotype and allele frequencies in SNP3, SNP4, and SNP6 were notably higher in the SCOS group than in the control group (P < .001). These results suggest that SEPTIN12 might play a critical role in human spermatogenesis.
- 6 May 2012
- Published by Wiley in Journal of Andrology
- Vol. 33 (3) , 483-487
Open AccessSingle‐Nucleotide Polymorphisms in the SEPTIN12 Gene May Be a Genetic Risk Factor for Japanese Patients With Sertoli Cell–Only Syndrome
Genetic mechanisms have been implicated as a cause of some cases of male infertility. Recently, 10 novel genes involved in human spermatogenesis, including human SEPTIN12, were identified by expression microarray analysis of human testicular tissue. Septin12 is a member of the septin family of conserved cytoskeletal GTPases that form heteropolymeric filamentous structures in interphase cells. It is expressed specifically in the testis. Therefore, we hypothesized that mutation or polymorphisms of SEPTIN12 participate in male infertility, especially Sertoli cell–only syndrome (SCOS). To investigate whether SEPTIN12 gene defects are associated with azoospermia caused by SCOS, mutational analysis was performed in 100 Japanese patients by direct sequencing of coding regions. Statistical analysis was performed in patients with SCOS and in 140 healthy control men. No mutations were found in SEPTIN12; however, 8 coding single‐nucleotide polymorphisms (SNP1–SNP8) could be detected in the patients with SCOS. The genotype and allele frequencies in SNP3, SNP4, and SNP6 were notably higher in the SCOS group than in the control group (P < .001). These results suggest that SEPTIN12 might play a critical role in human spermatogenesis.
- 30 March 2011
- Published by Wiley in International Journal of Urology
- Vol. 18 (6) , 469-471
Myelodysplastic syndrome treated effectively with testosterone enanthate
We report a case of myelodysplastic syndrome (MDS) treated effectively with testosterone enanthate. A 70-year-old man was diagnosed with low-risk MDS in 1998, and he was first given methenolone acetate orally because of gradual progression of anemia and thrombocytopenia. However, this treatment was not effective, so we changed the treatment to testosterone enanthate because of his symptoms with late-onset hypogonadism. Three months after testosterone replacement therapy (TRT), anemia and thrombocytopenia had improved, and mean platelet count and hemoglobin had significant increases from 2.36 ± 0.45 × 10(4) to 3.83 ± 0.78 × 10(4) /µL, and from 11.7 ± 0.81 to 15.2 ± 1.00 g/dL, respectively, which contributed to a decrease in platelet transfusion requirement. Since then, the patient has been on a good clinical course. The present case suggests that testosterone enanthate administration could be an alternative treatment for men with MDS, even in the case where treatment with anabolic-androgenic steroids is not successful, and suggests another interesting effect of TRT on platelets.
- 30 March 2011
- Published by Wiley in International Journal of Urology
- Vol. 18 (6) , 469-471
Myelodysplastic syndrome treated effectively with testosterone enanthate
We report a case of myelodysplastic syndrome (MDS) treated effectively with testosterone enanthate. A 70-year-old man was diagnosed with low-risk MDS in 1998, and he was first given methenolone acetate orally because of gradual progression of anemia and thrombocytopenia. However, this treatment was not effective, so we changed the treatment to testosterone enanthate because of his symptoms with late-onset hypogonadism. Three months after testosterone replacement therapy (TRT), anemia and thrombocytopenia had improved, and mean platelet count and hemoglobin had significant increases from 2.36 ± 0.45 × 10(4) to 3.83 ± 0.78 × 10(4) /µL, and from 11.7 ± 0.81 to 15.2 ± 1.00 g/dL, respectively, which contributed to a decrease in platelet transfusion requirement. Since then, the patient has been on a good clinical course. The present case suggests that testosterone enanthate administration could be an alternative treatment for men with MDS, even in the case where treatment with anabolic-androgenic steroids is not successful, and suggests another interesting effect of TRT on platelets.
- 1 December 2010
- Vol. 30 (12) , 5201-5
Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.
Ethinylestradiol was used as palliative treatment for patients with advanced prostate cancer (PCa). However, its use has declined after the development of combined androgen blockade. In the present study, we analyzed the effects of ethinylestradiol on pretreated castration-resistant PCa patients. Twenty-four Japanese patients were orally administered ethinylestradiol at a dose of 1.5 mg/day and prostate-specific antigen (PSA) was examined. We retrospectively analyzed the proportion of patients achieving a decline in PSA of >50% and progression-free and overall survival rates. All patients had already been treated with combined androgen blockade followed by one or more salvage therapies. Median follow-up time was 227 (range: 42-1490) days and median ethinylestradiol treatment time was 195 (range: 3-791) days. The proportion of patients achieving a decline in PSA >50% was 70%. Median progression-free survival was estimated as 300 days. At the end of the follow-up period, one patient had died from PCa. Adverse events occurred in three patients, namely elevation of liver enzymes, anorexia, and heart failure in one patient each. Oral ethinylestradiol administration may be useful for treatment of advanced castration-resistant PCa after salvage therapy with a high PSA response rate and low adverse event rate.
- 1 December 2010
- Vol. 30 (12) , 5201-5
Ethinylestradiol improves prostate-specific antigen levels in pretreated castration-resistant prostate cancer patients.
Ethinylestradiol was used as palliative treatment for patients with advanced prostate cancer (PCa). However, its use has declined after the development of combined androgen blockade. In the present study, we analyzed the effects of ethinylestradiol on pretreated castration-resistant PCa patients. Twenty-four Japanese patients were orally administered ethinylestradiol at a dose of 1.5 mg/day and prostate-specific antigen (PSA) was examined. We retrospectively analyzed the proportion of patients achieving a decline in PSA of >50% and progression-free and overall survival rates. All patients had already been treated with combined androgen blockade followed by one or more salvage therapies. Median follow-up time was 227 (range: 42-1490) days and median ethinylestradiol treatment time was 195 (range: 3-791) days. The proportion of patients achieving a decline in PSA >50% was 70%. Median progression-free survival was estimated as 300 days. At the end of the follow-up period, one patient had died from PCa. Adverse events occurred in three patients, namely elevation of liver enzymes, anorexia, and heart failure in one patient each. Oral ethinylestradiol administration may be useful for treatment of advanced castration-resistant PCa after salvage therapy with a high PSA response rate and low adverse event rate.
- Open Access
- 12 August 2010
- Published by Springer Nature in Journal of Human Genetics
- Vol. 55 (11) , 717-725
Human endogenous retrovirus K14C drove genomic diversification of the Y chromosome during primate evolution
The male-specific region of Y chromosome (MSY) has accumulated a higher density of human endogenous retroviruses (HERVs) and related sequences when compared with other regions of the human genome. Here, we focused on one HERV family, HERV-K14C that seemed to integrate preferentially into the Y chromosome in humans. To identify every copies of HERV-K14C in the human genome, we applied computational screening to map precisely the locus of individual HERV-K14C copies. Interestingly, 29 of all 146 copies were located in Y chromosome, and these 29 copies were mostly dispersed in the palindromic region. Three distinct HERV-K14C-related transcripts were found and were exclusively expressed in human testis tissue. Based on our phylogenetic analysis of the solitary LTRs derived from HERV-K14C on the Y chromosome we suggested that these sequences were generated as pairs of identical sequences. Specifically, analysis of HERV-K14C-related sequences in the palindromic region demonstrated that the Y chromosomal amplicons existed in our common ancestors and the duplicated pairs arose after divergence of great apes approximately 8–10 million years ago. Taken together, our observation suggested that HERV-K14C-related sequences contributed to genomic diversification of Y chromosome during speciation of great ape lineage.
- 12 August 2010
- Published by Springer Nature in Journal of Human Genetics
- Vol. 55 (11) , 717-725
Open AccessHuman endogenous retrovirus K14C drove genomic diversification of the Y chromosome during primate evolution
The male-specific region of Y chromosome (MSY) has accumulated a higher density of human endogenous retroviruses (HERVs) and related sequences when compared with other regions of the human genome. Here, we focused on one HERV family, HERV-K14C that seemed to integrate preferentially into the Y chromosome in humans. To identify every copies of HERV-K14C in the human genome, we applied computational screening to map precisely the locus of individual HERV-K14C copies. Interestingly, 29 of all 146 copies were located in Y chromosome, and these 29 copies were mostly dispersed in the palindromic region. Three distinct HERV-K14C-related transcripts were found and were exclusively expressed in human testis tissue. Based on our phylogenetic analysis of the solitary LTRs derived from HERV-K14C on the Y chromosome we suggested that these sequences were generated as pairs of identical sequences. Specifically, analysis of HERV-K14C-related sequences in the palindromic region demonstrated that the Y chromosomal amplicons existed in our common ancestors and the duplicated pairs arose after divergence of great apes approximately 8–10 million years ago. Taken together, our observation suggested that HERV-K14C-related sequences contributed to genomic diversification of Y chromosome during speciation of great ape lineage.
- 27 July 2010
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 25 (9) , 2396-2403
Features of constitutive gr/gr deletion in a Japanese population
BACKGROUND The relationship between male infertility and gr/gr deletions that remove multiple genes of the Y chromosome varies among countries and populations. The aim of this study was to investigate the association between gr/gr deletions and spermatogenic phenotype in fertile and infertile Japanese men. METHODS The subjects were screened by sequence-tagged site (STS) analysis to detect gr/gr deletions, and haplogroups were assigned using eight highly informative markers. In total, 395 infertile men and 377 fertile men (controls) participated in our study. Of the 772 subjects, 260 individuals carried confirmed gr/gr deletions and were used in further analysis of deletion subtype and gene copy number, specifically loss and gain of CDY1 and DAZ copies. These 260 subjects were divided into a control group (n = 131) all with normozoospermia, and an infertile group (n = 129) with 89 infertile subjects exhibiting azoospermia (absence of sperm) and 40 exhibiting oligozoospermia (reduced sperm concentration). RESULTS There were gr/gr deletions in 33.7% (260/772) of all subjects and the deletions were widespread in haplogroup D (86.2%). There were no significant differences in the frequency of gr/gr deletions between the infertile and control groups. The gr/gr deletion subtypes were not distributed randomly among haplogroups; the CDY1a+ DAZ1/2 genes were deleted in 96.9% (217/224) of haplogroup D individuals, whereas the O lineage had a variety of gr/gr deletion types. The loss of CDY1a+ DAZ1/2 was not associated with spermatogenic impairment in haplogroup D (P = 0.33). CONCLUSIONS Taken together, gr/gr deletions in haplogroup D occur constitutively, are associated with the loss of CDY1a + DAZ1/2 and are phenotypically neutral. Further studies are needed to establish whether Y-linked compensatory factors outside the AZFc region can counteract the pathogenic effect of a gr/gr deletion in the D lineage.
- 27 July 2010
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 25 (9) , 2396-2403
Features of constitutive gr/gr deletion in a Japanese population
BACKGROUND The relationship between male infertility and gr/gr deletions that remove multiple genes of the Y chromosome varies among countries and populations. The aim of this study was to investigate the association between gr/gr deletions and spermatogenic phenotype in fertile and infertile Japanese men. METHODS The subjects were screened by sequence-tagged site (STS) analysis to detect gr/gr deletions, and haplogroups were assigned using eight highly informative markers. In total, 395 infertile men and 377 fertile men (controls) participated in our study. Of the 772 subjects, 260 individuals carried confirmed gr/gr deletions and were used in further analysis of deletion subtype and gene copy number, specifically loss and gain of CDY1 and DAZ copies. These 260 subjects were divided into a control group (n = 131) all with normozoospermia, and an infertile group (n = 129) with 89 infertile subjects exhibiting azoospermia (absence of sperm) and 40 exhibiting oligozoospermia (reduced sperm concentration). RESULTS There were gr/gr deletions in 33.7% (260/772) of all subjects and the deletions were widespread in haplogroup D (86.2%). There were no significant differences in the frequency of gr/gr deletions between the infertile and control groups. The gr/gr deletion subtypes were not distributed randomly among haplogroups; the CDY1a+ DAZ1/2 genes were deleted in 96.9% (217/224) of haplogroup D individuals, whereas the O lineage had a variety of gr/gr deletion types. The loss of CDY1a+ DAZ1/2 was not associated with spermatogenic impairment in haplogroup D (P = 0.33). CONCLUSIONS Taken together, gr/gr deletions in haplogroup D occur constitutively, are associated with the loss of CDY1a + DAZ1/2 and are phenotypically neutral. Further studies are needed to establish whether Y-linked compensatory factors outside the AZFc region can counteract the pathogenic effect of a gr/gr deletion in the D lineage.